share_log

IX Biopharma Widens Net Loss by 12% in FY2024

Singapore Business Review ·  Aug 27 04:51

Loss per share stood at $0.0141.

iX Biopharma reported a net loss by 12% to $10.8m in FY2024 from $9.6m a year ago.

Revenue for the period slipped 1% to $5.95m from $5.91m in FY2023, whilst gross profit fell 55% to $1.04m from $2.32m in FY2023.

Loss per share stood at $0.0141 from $0.0126 a year ago.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment